GAB2 induces tumor angiogenesis in NRAS-driven melanoma

Oncogene

Volumn 32, Issue 31, 2013, Pages 3627-3637

  Yang, Y ^a   Wu, J ^a   Demir, A ^a   Castillo Martin, M ^b   Melamed, R D ^a   Zhang, G ^c   Fukunaga Kanabis, M ^c   Perez Lorenzo, R ^a   Zheng, B ^a   Silvers, D N ^a   Brunner, G ^d   Wang, S ^a   Rabadan, R ^a   Cordon Cardo, C ^b   Celebi, J T ^a  

^a Columbia University ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c WISTAR INSTITUTE   (United States)

^d Fachklinik Hornheide ^*  (Germany)

Author keywords

adaptor; angiogenesis; melanoma; scaffold

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; CD34 ANTIGEN; GAB2 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN BCL 2; PROTEIN KINASE B; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANCHORAGE INDEPENDENT GROWTH; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTASIS POTENTIAL; METASTATIC MELANOMA; MOUSE; NONHUMAN; ONCOGENE N RAS; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STABLE EXPRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFANT, NEWBORN; MELANOMA; MEMBRANE PROTEINS; MICE; MUTATION; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PROTO-ONCOGENE PROTEINS B-RAF; RATS; TRANSCRIPTION, GENETIC; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84881219979     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.367     Document Type: Article

References (54)

1. Gu H, Pratt JC, Burakoff SJ, Neel BG. Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol Cell 1998; 2: 729-740.
2. Gu H, Neel BG. The 'Gab' in signal transduction. Trends Cell Biol 2003; 13: 122-130.
3. Wohrle FU, Daly RJ, Brummer T. Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal 2009; 7: 22.
4. Nishida K, Hirano T. The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci 2003; 94: 1029-1033.
5. Bennett HL, Brummer T, Jeanes A, Yap AS, Daly RJ. Gab2and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis. Oncogene 2008; 27: 2693-2704.
6. Sun J, Pedersen M, Ronnstrand L. Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit. J Biol Chem 2008; 283: 27444-27451.
7. Lock LS, Maroun CR, Naujokas MA, Park M. Distinct recruitment and function of Gab1 and Gab2 in Met receptor-mediated epithelial morphogenesis. Mol Biol Cell 2002; 13: 2132-2146.
8. Mao Y, Lee AW. A novel role for Gab2 in bFGF-mediated cell survival during retinoic acid-induced neuronal differentiation. J Cell Biol 2005; 170: 305-316.
9. Meng S, Chen Z, Munoz-Antonia T, Wu J. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor. Biochem J 2005; 391: 143-151.
10. Kameda H, Ishigami H, Suzuki M, Abe T, Takeuchi T. Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. Clin Exp Immunol 2006; 144: 335-341.
11. D'Alessio A, Cerchia L, Amelio I, Incoronato M, Condorelli G, de Franciscis V. Shp2 in PC12 cells: NGF versus EGF signalling. Cell Signal 2007; 19: 1193-1200.
12. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002; 1: 479-492.
13. Bentires-Alj M, Gil SG, Chan R, Wang ZC, Wang Y, Imanaka N et al. A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 2006; 12: 114-121.
14. Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J et al. Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 2010; 29: 774-779.
15. Ke Y, Wu D, Princen F, Nguyen T, Pang Y, Lesperance J et al. Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene 2007; 26: 4951-4960.
16. Brown LA, Kalloger SE, Miller MA, Shih IeM, McKinney SE, Santos JL et al. Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 2008; 47: 481-489.
17. Zatkova A, Schoch C, Speleman F, Poppe B, Mannhalter C, Fonatsch C et al. GAB2 is a novel target of 11q amplification in AML/MDS. Genes Chromosomes Cancer 2006; 45: 798-807.
18. Horst B, Gruvberger-Saal SK, Hopkins BD, Bordone L, Yang Y, Chernoff KA et al. Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol 2009; 174: 1524-1533.
19. Chernoff K, Bordone L, Horst B, Simon K, Twaddell WS, Lee K et al. Gab2 amplifications refine molecular classification of melanoma. Clin Cancer Res 2009; 15: 4288-4291.
20. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics 2006. CA Cancer J Clin 2006; 56: 106-130.
21. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300.
22. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
23. Ghosh P, Chin L. Genetics and genomics of melanoma. Expert Rev Dermatol 2009; 4: 131.
24. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445: 851-857.
25. Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res 2006; 66: 6503-6511.
26. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 2001; 21: 2144-2153.
27. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997; 11: 2822-2834.
28. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 2005; 65: 4005-4011.
29. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004; 64: 2338-2342.
30. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 2005; 37: 745-749.
31. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr WE et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41: 544-552.
32. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am 2011; 20: 1-17.
33. Gershenwald JE, Soong SJ, Balch CM. TNM staging system for cutaneous melanoma. and beyond. Ann Surg Oncol 2010; 17: 1475-1477.
34. Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987; 39: 414-418.
35. Monsel G, Ortonne N, Bagot M, Bensussan A, Dumaz N. c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 2010; 29: 227-236.
36. Mishra PJ, Ha L, Rieker J, Sviderskaya EV, Bennett DC, Oberst MD et al. Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene 2010; 29: 2449-2456.
37. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE et al. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA 2007; 104: 10968-10973.
38. Tsatsanis C, Spandidos DA. Oncogenic kinase signaling in human neoplasms. Ann N Y Acad Sci 2004; 1028: 168-175.
39. Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res 2010; 70: 5549-5557.
40. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011; 2: 359-372.
41. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3: 411-421.
42. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
43. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008; 27: 5132-5137.
44. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
45. Gerhardt H. VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 2008; 4: 241-246.
46. Kranenburg O, Gebbink MF, Voest EE. Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta 2004; 1654: 23-37.
47. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997; 94: 861-866.
48. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
49. Wozniak A. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Crit Rev Oncol Hematol 2012; 82: 200-212.
50. Dance M, Montagner A, Yart A, Masri B, Audigier Y, Perret B et al. The adaptor protein Gab1 couples the stimulation of vascular endothelial growth factor receptor-2 to the activation of phosphoinositide 3-kinase. J Biol Chem 2006; 281: 23285-23295.
51. Caron C, Spring K, Laramee M, Chabot C, Cloutier M, Gu H et al. Non-redundant roles of the Gab1 and Gab2 scaffolding adapters in VEGF-mediated signalling, migration, and survival of endothelial cells. Cell Signal 2009; 21: 943-953.
52. Laramee M, Chabot C, Cloutier M, Stenne R, Holgado-Madruga M, Wong AJ et al. The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation. J Biol Chem 2007; 282: 7758-7769.
53. Lu Y, Xiong Y, Huo Y, Han J, Yang X, Zhang R et al. Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway. Proc Natl Acad Sci USA 2011; 108: 2957-2962.
54. Berking C, Takemoto R, Satyamoorthy K, Shirakawa T, Eskandarpour M, Hansson J et al. Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res 2004; 64: 807-811.